Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS
The aim of HARMONY PLUS is to build on HARMONY’s work. The project will add the following blood cancers to the list of diseases under study: chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; as well as Hodgkin’s lymphoma, Waldenström macroglobulinemia and other rare blood cancers not covered by HARMONY. In addition, HARMONY PLUS will help to convert the existing HARMONY platform into an integrated services platform that could serve clinicians to improve their decision-making process and support clinical trial design, among other things.
HARMONY PLUS was established October 2020 with funding from the Innovative Medicine Initiative (IMI) and involves 39 partners and 8 Associated Partners from 10 countries. The project involves the European pharmaceutical industry (via EFPIA), universities, research organisations, public bodies, patient organisations, HTA and SMEs partners.